Compare · ALNY vs LONA

ALNY vs LONA

Side-by-side comparison of Alnylam Pharmaceuticals Inc. (ALNY) and LeonaBio Inc. (LONA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. ALNY focuses on Biotechnology: Pharmaceutical Preparations, while LONA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • ALNY is the larger of the two at $19.80B, about 615.5x LONA ($32.2M).
  • ALNY has been more active in the news (23 items in the past 4 weeks vs 7 for LONA).
  • ALNY has more recent analyst coverage (25 ratings vs 4 for LONA).
MetricALNYLONA
Company
Alnylam Pharmaceuticals Inc.
LeonaBio Inc.
Price
-
-
Market cap
$19.80B
$32.2M
1M return
-35.63%
-
1Y return
-67.18%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2004
2020
News (4w)
23
7
Recent ratings
25
4
ALNY

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Latest ALNY

Latest LONA